BIOVECTRA, an element of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that offers BIOVECTRA access to Revolution Biomanufacturing’s proprietary platforms for optimizing untranslated regions (UTRs) and codon usage to enhance mRNA stability and translation efficiency. This partnership provides a completely integrated path from mRNA sequence design to sterile drug product manufacturing, […]
